Bmi Doctors

is semaglutide like victoza 1

Is Semaglutide Like Victoza? Key Differences, Similarities, and What You Should Know

by

Table of Contents

Introduction

In the last several years, new medicines have changed how doctors treat type 2 diabetes and weight management. Two of the most talked about medications are semaglutide and Victoza. People often ask if they are the same, if they work in the same way, or if one is better than the other. This confusion makes sense, because both drugs belong to the same class of medicines called GLP-1 receptor agonists. These medicines copy a hormone that the body naturally makes, which helps control blood sugar and appetite. But while semaglutide and Victoza share some important features, they also have key differences that affect how they are used, how often they are taken, and what results patients may expect.

Understanding how these two drugs compare is important for people living with type 2 diabetes or obesity, as well as for families and caregivers who want to support them. Diabetes and obesity are long-term conditions that require careful planning and treatment. A medication that works well for one person may not work the same way for someone else. Knowing the similarities and differences between semaglutide and Victoza can help patients ask the right questions and make informed choices with their healthcare providers.

Why are these medications compared so often? Both semaglutide and Victoza are designed to help lower blood sugar in people with type 2 diabetes. Both can also help with weight loss. In fact, each medication has versions that are approved by the U.S. Food and Drug Administration (FDA) not just for diabetes, but also for obesity. Semaglutide is the main ingredient in Ozempic, Wegovy, and Rybelsus, while Victoza contains liraglutide, which is also used in Saxenda. This overlap in their use can make it hard to tell them apart. Many people search online to find out if one is stronger, safer, or better suited for them.

One of the most noticeable differences is how often they are taken. Semaglutide is usually given once a week, while Victoza is taken once a day. This may sound like a small detail, but for many patients, convenience matters a lot when sticking to a treatment plan. Another major difference is that semaglutide comes in an oral pill form, called Rybelsus, while Victoza only comes as an injection. These differences in how the medicines are given can affect patient preference and comfort.

Both medicines have been shown in large clinical studies to lower blood sugar (measured as A1C levels) and to reduce weight. But the amount of improvement can vary. Research shows that semaglutide may lead to larger reductions in both blood sugar and body weight compared to Victoza. At the same time, both medications carry risks and side effects, such as nausea, vomiting, and sometimes more serious issues like pancreatitis or gallbladder disease. Because of these risks, doctors look closely at each patient’s health history before deciding which medicine to prescribe.

Another important part of the discussion is heart health. People with type 2 diabetes often have a higher risk of heart disease and stroke. Both semaglutide and Victoza have been studied in special trials that look at cardiovascular outcomes. These studies show that both drugs can reduce the risk of major heart events in certain patients. This makes them valuable not just for blood sugar control, but also for protecting long-term health.

The goal of this article is to make the comparison between semaglutide and Victoza as clear as possible. Many patients search the internet with questions like: “Is semaglutide like Victoza?”, “Which one works better?”, or “Do they have the same side effects?” In the pages ahead, we will look at the science, the approvals, the benefits, and the risks. We will go step by step through what each medicine does, how it is given, what conditions it is approved to treat, and what differences matter most for people thinking about these treatments.

It is also important to note that this article is not meant to replace medical advice. Every patient’s situation is unique. Factors such as other health conditions, insurance coverage, medication tolerance, and lifestyle all play a role in choosing the right treatment. But by understanding the similarities and differences between semaglutide and Victoza, readers will be better prepared to talk with their healthcare team and make choices that fit their needs.

In summary, semaglutide and Victoza are often compared because they are in the same drug class, treat similar conditions, and have overlapping benefits. At the same time, they differ in how they are taken, how often they are used, and in some of their clinical results. This article will break down these details in a simple, clear way, focusing on the top questions people ask. By the end, readers should have a full picture of what makes semaglutide and Victoza similar, what sets them apart, and what key facts they should know before starting a conversation with their doctor.

Change Your Life Today For Only $249/month

Find out if you qualify
No Hidden Fees, No Contracts

What Are Semaglutide and Victoza?

When people first hear about semaglutide and Victoza, it can be confusing because both are medicines used for diabetes and sometimes weight problems. They also work in similar ways since they belong to the same family of drugs, called GLP-1 receptor agonists. Even though they share similarities, they are not the same drug. To understand them better, let’s look at what each one is, where it comes from, and how doctors use them.

Semaglutide: What It Is

Semaglutide is the name of the active drug. It is sold under different brand names, each with its own purpose:

  • Ozempic – an injection taken once a week, used for type 2 diabetes.

  • Wegovy – also an injection once a week, but this version is approved mainly for weight loss in people with obesity or overweight plus related health conditions.

  • Rybelsus – a pill form of semaglutide that you swallow daily, approved for type 2 diabetes.

Semaglutide was first approved by the U.S. Food and Drug Administration (FDA) in 2017 under the name Ozempic. Wegovy came later in 2021, and Rybelsus was approved in 2019. The company that makes semaglutide is Novo Nordisk, a global pharmaceutical company based in Denmark.

What makes semaglutide stand out is the fact that it can be taken once a week (for the injection form). This is different from many older diabetes medicines that needed to be taken once or even twice a day. This weekly schedule makes it easier for some people to stick to their treatment.

Victoza: What It Is

Victoza is the brand name for another medicine called liraglutide. Like semaglutide, it is a GLP-1 receptor agonist. Novo Nordisk also developed and sells Victoza. It was approved earlier than semaglutide—in 2010—for the treatment of type 2 diabetes.

Unlike semaglutide, Victoza is not taken once a week. Instead, it is injected once every day. The injection device is a prefilled pen, and patients give themselves the shot under the skin, usually in the stomach, thigh, or upper arm.

Another important fact is that a higher dose of liraglutide is also sold under a different brand name, Saxenda. Saxenda is approved specifically for weight management in people who are obese or overweight with weight-related health conditions. So, while Victoza is for type 2 diabetes, Saxenda is for weight loss.

Why People Compare Them

People often compare semaglutide and Victoza because:

  1. Same drug family: Both belong to the GLP-1 receptor agonist class.

  2. Same company: They are both made by Novo Nordisk.

  3. Similar uses: Both help lower blood sugar in people with type 2 diabetes and can help with weight loss.

  4. Different schedules: One is once a week, while the other is once daily.

Because they are related in these ways, many patients and caregivers ask, “Is semaglutide just another version of Victoza?” The answer is no—they are related, but they are not the same drug.

How They Are Used in Treatment

Doctors prescribe these medicines for people with type 2 diabetes when other treatments such as diet, exercise, or pills like metformin are not enough to control blood sugar. Both semaglutide and Victoza help lower A1C levels, which measure average blood sugar over time. They also slow digestion and reduce appetite, which helps many patients lose weight.

For weight management alone, doctors usually prescribe Wegovy (semaglutide) or Saxenda (liraglutide) instead of Victoza or Ozempic. This is because the FDA approved these versions specifically for obesity care.

FDA Approvals at a Glance

  • Semaglutide

    • Ozempic (2017): Type 2 diabetes.

    • Rybelsus (2019): Type 2 diabetes (oral pill).

    • Wegovy (2021): Chronic weight management.

  • Victoza (liraglutide)

    • Approved in 2010: Type 2 diabetes.

    • Saxenda (higher-dose liraglutide, 2014): Chronic weight management.

Semaglutide and Victoza are different drugs, but they are part of the same larger family of medicines. Semaglutide comes in weekly injections and even in a pill form, while Victoza must be injected daily. Both lower blood sugar and can help with weight loss, but their specific approvals and dosing schedules are not the same. Knowing these basics makes it easier to understand the differences when comparing them side by side.

How Do Semaglutide and Victoza Work in the Body?

Semaglutide and Victoza belong to a group of medicines called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, which is a natural hormone in the body. This hormone is released in the gut, mainly after eating, and plays an important role in controlling blood sugar and appetite.

When you take semaglutide or Victoza, the medicine acts like GLP-1, but with a much stronger and longer effect than the natural hormone. To understand how these drugs work, let’s break down their main actions in the body.

Stimulating Insulin Release

One of the key jobs of GLP-1 is to help the pancreas release insulin. Insulin is the hormone that lowers blood sugar by moving glucose (sugar) out of the bloodstream and into cells, where it is used for energy.

  • In people with type 2 diabetes, the body does not make enough insulin or does not use it well.

  • Both semaglutide and Victoza help the pancreas release more insulin, but only when blood sugar is high.

  • This “glucose-dependent” action means they reduce the risk of dangerously low blood sugar (hypoglycemia) compared to some older diabetes medicines.

This effect helps people keep their blood sugar levels more stable, especially after meals.

Lowering Glucagon Levels

Glucagon is another hormone made by the pancreas. It has the opposite effect of insulin—it raises blood sugar by signaling the liver to release stored glucose.

  • In type 2 diabetes, glucagon levels can be too high, which causes the liver to release too much sugar into the blood.

  • Semaglutide and Victoza reduce glucagon secretion when it is not needed.

  • By lowering glucagon, these medicines prevent extra sugar from flooding the bloodstream.

This dual action—more insulin and less glucagon—creates better balance and smoother control of blood sugar.

Slowing Down Digestion

Another important way these drugs work is by slowing the emptying of the stomach. Normally, after a meal, food moves fairly quickly from the stomach into the small intestine. With semaglutide or Victoza, this process is slower.

  • A slower digestion rate means glucose from food enters the blood more gradually.

  • This prevents sharp spikes in blood sugar after eating.

  • It also helps people feel full for longer, which can reduce hunger and lower calorie intake.

This effect on appetite is one of the reasons why both medications are linked to weight loss in many patients.

Acting on the Brain to Reduce Appetite

GLP-1 receptors are not just in the gut and pancreas. They are also found in areas of the brain that control hunger and fullness.

  • When semaglutide or Victoza activate these receptors, they send signals that reduce appetite.

  • People often report feeling satisfied with smaller meals.

  • Over time, this can lead to steady and meaningful weight loss, especially when combined with diet and lifestyle changes.

This brain effect is stronger with semaglutide compared to Victoza, which helps explain why semaglutide is often more effective for weight management.

Protecting the Heart and Blood Vessels

Although this action is not as obvious as blood sugar control, GLP-1 receptor agonists also seem to have benefits for the cardiovascular system. Clinical studies show that both semaglutide and Victoza can lower the risk of heart attack, stroke, and death from heart-related causes in people with type 2 diabetes and heart disease.

The reasons are not fully understood, but researchers believe these drugs may:

  • Improve blood pressure.

  • Reduce body weight and harmful cholesterol levels.

  • Improve the function of blood vessel walls.

This makes semaglutide and Victoza especially important for people with type 2 diabetes, who are already at higher risk of heart problems.

How They Differ in the Body

While semaglutide and Victoza share the same general way of working, there are some differences in how long they act in the body:

  • Semaglutide lasts much longer, so it can be taken once a week.

  • Victoza (liraglutide) has a shorter action, so it needs to be taken once daily.

Both medicines are designed to resist being broken down quickly by natural enzymes. This is why they can work effectively even though natural GLP-1 normally disappears from the body within just a few minutes.

is semaglutide like victoza 2

What Conditions Do They Treat?

Semaglutide and Victoza are both medicines that belong to a group called GLP-1 receptor agonists. They are often prescribed for people with type 2 diabetes, but each drug also has other approved uses. Understanding what conditions these medicines treat is important because it helps patients and caregivers know why a doctor may recommend one over the other.

Semaglutide

Semaglutide is the active ingredient in several brand-name medicines. Each brand is approved for slightly different purposes.

  • Ozempic: This is an injectable medicine taken once a week. The U.S. Food and Drug Administration (FDA) approved Ozempic in 2017. Its main use is to improve blood sugar control in adults with type 2 diabetes. It is also approved to reduce the risk of major heart problems, such as heart attack, stroke, or death, in adults with type 2 diabetes and heart disease.

  • Wegovy: This is also an injectable form of semaglutide, given once a week. It was approved in 2021. Wegovy is prescribed for weight management in adults who are either obese or overweight and who also have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. It is also approved for certain teenagers (ages 12 and older) with obesity. Wegovy is not mainly used to control blood sugar, though it may improve it in people who also have diabetes.

  • Rybelsus: This is the first oral (tablet) form of semaglutide. It was approved in 2019. Rybelsus is taken once daily and is used to improve blood sugar in adults with type 2 diabetes. Unlike Ozempic, Rybelsus is not currently approved for weight loss or for lowering heart disease risk, though some people may still lose weight while taking it.

In short, semaglutide medicines are used to treat type 2 diabetes, obesity, and to reduce cardiovascular risk in people with diabetes and existing heart disease. The exact use depends on the brand and form.

Victoza (Liraglutide)

Victoza is the brand name for liraglutide, another GLP-1 receptor agonist. It was approved earlier than semaglutide, in 2010. Like semaglutide, it has specific uses depending on the product and dose.

  • Victoza: This is a once-daily injectable medicine. It is approved to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. It also has approval to reduce the risk of major heart problems in adults with type 2 diabetes and heart disease.

  • Saxenda: This is a higher-dose form of liraglutide. It was approved in 2014. Saxenda is used for long-term weight management in adults who are obese or overweight and who also have at least one weight-related health problem, such as high blood pressure, type 2 diabetes, or high cholesterol. Saxenda is also approved for teenagers ages 12 to 17 with obesity who weigh more than 132 pounds (60 kg).

In summary, liraglutide medicines are used to treat type 2 diabetes, obesity, and to reduce cardiovascular risk in people with diabetes and heart disease, much like semaglutide. However, dosing schedules and approved age ranges differ.

Comparing Their Approved Uses

Both semaglutide and liraglutide have three main areas of treatment:

  1. Type 2 Diabetes

    • Ozempic, Rybelsus, and Victoza are approved for type 2 diabetes.

    • They help lower blood sugar by helping the body release more insulin when needed and slowing how quickly food leaves the stomach.

    • These medicines are not used for type 1 diabetes or for diabetic ketoacidosis.

  2. Weight Management

    • Wegovy and Saxenda are approved for weight management.

    • Both are used in adults who are obese (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related health issue.

    • Both are also approved for some teenagers with obesity, but Wegovy is approved for ages 12 and up with no weight minimum, while Saxenda requires a weight of at least 132 pounds (60 kg).

  3. Cardiovascular Risk Reduction

    • Ozempic and Victoza are both approved to reduce the risk of heart attack, stroke, or cardiovascular death in adults with type 2 diabetes and existing heart disease.

    • This benefit is important because people with type 2 diabetes often face higher risks of heart problems.

Semaglutide and Victoza both treat type 2 diabetes, support weight loss in certain patients, and lower the risk of serious heart problems in people with diabetes and heart disease. The main differences are in the brand names, forms of medicine (injection vs. pill), dosing schedules, and specific approvals for weight management or age groups.

What Are the Key Differences Between Semaglutide and Victoza?

Although semaglutide and Victoza (liraglutide) are both medications in the same drug class, they are not identical. They share the same overall purpose—helping people with type 2 diabetes manage blood sugar—but there are many differences in how they are made, how they are taken, and what conditions they are approved to treat. Understanding these key differences is important for anyone learning about these drugs or comparing them.

Molecular Differences

The first difference lies in the molecules themselves.

  • Semaglutide and liraglutide (Victoza) are both man-made versions of a natural hormone in the body called GLP-1 (glucagon-like peptide-1). This hormone helps control blood sugar and appetite.

  • However, semaglutide and liraglutide are built slightly differently at the molecular level. These changes affect how long they stay active in the body.

  • Semaglutide lasts longer in the body because its chemical structure is designed to resist breakdown and to bind more strongly to proteins in the blood. This is why it can be taken once a week.

  • Liraglutide does not last as long. It breaks down faster, so it must be taken every day to keep blood levels steady.

This difference in duration is one of the most important distinctions between the two medicines.

Dosing Frequency (Weekly vs. Daily)

How often someone takes the medicine is a major difference.

  • Semaglutide is usually given once a week by injection. This is considered more convenient by many patients because they only need to think about it once every seven days.

  • Victoza (liraglutide), on the other hand, is injected once daily. This means patients must remember to take it every day around the same time.

The weekly versus daily schedule can play a big role in treatment choice. For some, the daily routine of Victoza helps them stay consistent. For others, the weekly option of semaglutide fits better into their lifestyle.

Delivery Methods

Both medicines come as injections, but semaglutide also offers something extra.

  • Semaglutide is available in several forms:

    • Ozempic: a weekly injection for type 2 diabetes.

    • Wegovy: a weekly injection for weight management.

    • Rybelsus: a pill form of semaglutide, taken once daily by mouth. This makes it the first GLP-1 receptor agonist available in tablet form.

  • Victoza (liraglutide) is only available as an injection. There is no pill form.

The oral form of semaglutide gives doctors and patients another option, especially for people who are nervous about injections.

Weight Management Approvals

Another big difference is approval for weight management.

  • Semaglutide (Wegovy) has been approved by the FDA for the treatment of obesity or overweight in adults with certain health conditions. Clinical trials showed it could help people lose a significant amount of body weight.

  • Liraglutide (Saxenda), a higher-dose version of the same drug as Victoza, is also approved for weight management. However, Victoza itself is not marketed for weight loss—it is specifically approved for type 2 diabetes and for reducing the risk of certain heart problems.

This means that while both semaglutide and liraglutide have roles in weight control, semaglutide tends to be associated with greater weight loss in studies, and Wegovy has gained more attention for obesity treatment.

Why These Differences Matter

The differences between semaglutide and Victoza affect real-world use:

  • Convenience: A weekly dose may improve adherence for some patients. Others may prefer daily dosing as part of a routine.

  • Flexibility: Having both injectable and oral forms of semaglutide gives patients and doctors more options.

  • Health goals: If a patient’s primary goal is weight loss, semaglutide may be the first choice because of Wegovy’s approval and trial results. If daily blood sugar control is the main focus, Victoza may still be an effective option.

While both medications belong to the same drug family, the differences in molecular design, dosing schedule, delivery methods, and approvals make semaglutide and Victoza unique. These differences are not just scientific details—they influence convenience, effectiveness, and the role each drug plays in diabetes and weight management treatment.

Change Your Life Today For Only $249/month

Find out if you qualify
No Hidden Fees, No Contracts

What Are the Similarities Between Semaglutide and Victoza?

Semaglutide and Victoza are often compared because they belong to the same group of medicines called GLP-1 receptor agonists. These drugs were developed to help people with type 2 diabetes lower their blood sugar levels and improve overall health. Over time, they have also been found to help with weight management and to lower the risk of heart problems in certain patients. Even though they are different medicines, they share many features. Below, we will look at the main similarities in detail.

Both Belong to the Same Drug Class

Semaglutide and Victoza are both glucagon-like peptide-1 (GLP-1) receptor agonists. This means they act like a natural hormone in the body called GLP-1. This hormone is released in the gut after eating and helps control blood sugar. By mimicking GLP-1, both drugs increase the release of insulin, decrease the release of glucagon (another hormone that raises blood sugar), and slow down the emptying of the stomach. This shared mechanism explains why the two medicines have overlapping benefits.

Both Improve Blood Sugar Control

One of the main reasons doctors prescribe either semaglutide or Victoza is to help control blood sugar in people with type 2 diabetes. Both medicines can:

  • Lower fasting blood glucose (the level after not eating for several hours).

  • Reduce post-meal glucose spikes.

  • Lower hemoglobin A1C, which shows average blood sugar levels over the last 2–3 months.

While the degree of improvement may differ between the two drugs, the fact that they both significantly improve blood sugar control makes them similar in clinical practice.

Both Support Weight Reduction

Weight loss is another shared benefit. Because these medicines slow stomach emptying and increase feelings of fullness, many people eat less and lose weight over time. Both semaglutide and Victoza are known for this effect, though clinical studies suggest semaglutide often leads to greater weight loss. Still, the fact remains that both drugs are useful not only for blood sugar control but also for managing body weight, which is important for many patients with type 2 diabetes.

Both Share Common Side Effects

Since semaglutide and Victoza work in similar ways, they often cause similar side effects. The most common ones include:

  • Nausea

  • Vomiting

  • Diarrhea

  • Constipation

  • Abdominal pain

These symptoms are usually mild and improve as the body adjusts to the medicine. Doctors often start patients on a low dose and increase slowly to reduce these effects. Both medicines also carry warnings about more serious risks, such as pancreatitis (inflammation of the pancreas), gallbladder problems, and a possible link to thyroid tumors in animal studies. Because these risks are similar, doctors monitor patients closely regardless of which drug is prescribed.

Both Lower Cardiovascular Risk

A major discovery about GLP-1 receptor agonists is that they not only lower blood sugar but also protect the heart in certain patients. Large clinical trials have shown that both semaglutide and liraglutide (Victoza) reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who already have heart disease. This is a very important similarity because it means both drugs are not just treating diabetes—they are also helping people live longer and healthier lives.

Both Are Injectable Medications

Although semaglutide also comes in an oral form (Rybelsus), both medicines are best known as injections. They are given with a prefilled pen that patients can use at home after proper training. Both require small, under-the-skin injections, usually in the abdomen, thigh, or upper arm. The design of the pens is similar, and both aim to make the process easy for patients to self-administer.

Both Require Medical Supervision

Finally, both semaglutide and Victoza must be prescribed and monitored by a healthcare professional. Neither is available over the counter. Doctors decide which one to use based on a patient’s health history, goals, and tolerance of side effects. Both medicines require ongoing check-ups, blood tests, and lifestyle support to work effectively and safely.

is semaglutide like victoza 3

Which One Works Better for Blood Sugar Control?

When comparing semaglutide and Victoza (liraglutide), one of the most important questions is how well they lower blood sugar levels. Both belong to the same drug class, called GLP-1 receptor agonists, and both help people with type 2 diabetes lower their blood sugar and improve A1C. But there are some clear differences in how much they lower A1C, how long they last in the body, and how people respond to them. Let’s break it down step by step.

Understanding A1C and Blood Sugar Control

Before comparing the two medicines, it helps to understand A1C. The A1C test measures the average blood sugar over the last two to three months. For most adults with type 2 diabetes, the general target is an A1C of below 7%, though personal targets can differ. Lowering A1C reduces the risk of long-term complications, such as kidney damage, eye problems, and nerve damage.

Both semaglutide and liraglutide lower blood sugar by:

  • Increasing insulin release after meals.

  • Reducing glucagon (a hormone that raises blood sugar).

  • Slowing down digestion, so glucose enters the blood more steadily.

This shared mechanism explains why both drugs improve A1C, but clinical trials show semaglutide usually lowers it a bit more.

Clinical Trial Comparisons

Large clinical trials have tested semaglutide and liraglutide separately and sometimes head-to-head. The results consistently show that semaglutide lowers A1C more than liraglutide.

  • Semaglutide (Ozempic): In studies, weekly injections of semaglutide lowered A1C by about 1.5% to 2% on average, depending on the dose. Some people saw even greater reductions, especially when starting with higher baseline A1C.

  • Liraglutide (Victoza): In studies, daily injections of liraglutide lowered A1C by about 1% to 1.5% on average.

One of the most direct comparisons was the SUSTAIN 10 trial, where semaglutide (once weekly) was compared directly to liraglutide (once daily). Semaglutide reduced A1C by about 1.7%, compared with about 1.0% for liraglutide. This shows semaglutide’s stronger effect.

Duration of Action

Another reason semaglutide often works better is how long it stays in the body.

  • Semaglutide: Has a much longer half-life, which means it lasts in the body for about a week. This provides steady control of blood sugar with just one injection per week.

  • Liraglutide: Lasts for about 24 hours, so it must be taken once daily to keep the effect going.

Because semaglutide provides a steadier effect, some people see better day-to-day blood sugar control and fewer ups and downs.

Impact on Fasting vs. After-Meal Blood Sugars

Both medicines help with fasting blood sugar (the level after not eating for at least 8 hours) and post-meal blood sugar (the level after eating).

  • Semaglutide: Has been shown to have a stronger effect on fasting glucose, bringing down morning numbers more consistently.

  • Liraglutide: Still lowers fasting glucose, but the effect is sometimes a little less strong compared with semaglutide.

For after-meal glucose, both medicines slow digestion and reduce glucose spikes, but semaglutide again has a slightly stronger impact.

Patient Response Variability

It is important to note that not everyone responds the same way. Some people may respond very well to liraglutide, with A1C improvements equal to those seen with semaglutide. Others may experience more side effects with semaglutide, making liraglutide a better option even if the average A1C reduction is lower. Doctors usually consider personal history, tolerance, and lifestyle when deciding which medicine is the better fit.

Combination with Other Medications

Both semaglutide and liraglutide can be used alone or in combination with other diabetes medicines, such as metformin, SGLT2 inhibitors, or insulin. When added to these regimens, both improve A1C further, but studies again show semaglutide tends to give an extra edge in lowering blood sugar.

While both medications are effective for managing blood sugar in type 2 diabetes, semaglutide generally works better than liraglutide for lowering A1C and providing long-term glucose control. However, the “best” medicine depends on the individual. Some people may tolerate liraglutide better or may prefer daily dosing, while others may see more benefit with semaglutide’s once-weekly schedule and stronger A1C reduction. Doctors use both options, tailoring the choice to each patient’s needs.

Which One Is More Effective for Weight Loss?

Both semaglutide and Victoza (liraglutide) belong to the same family of medicines called GLP-1 receptor agonists. While both help lower blood sugar, many people and doctors also pay attention to how these drugs affect body weight. Weight loss is an important topic because extra weight can make type 2 diabetes harder to control and raise the risk of heart disease. In this section, we will look closely at how semaglutide and Victoza compare when it comes to weight loss.

How They Affect Weight

Semaglutide and Victoza work in a similar way to help with weight loss. They slow down how quickly food leaves the stomach, which makes you feel full for longer. They also act on areas in the brain that control hunger, leading to less appetite and fewer cravings. By eating less food, people can gradually lose weight while using these medicines.

Even though the way they work is similar, the amount of weight loss seen with each medicine is not the same. Clinical trials show that semaglutide usually leads to greater weight loss than Victoza. The differences can be explained by the drug’s strength, how long it lasts in the body, and how it is given.

Clinical Trial Results for Semaglutide

Semaglutide has been studied in many large trials, including the STEP program, which focused on weight management. In these studies, people without diabetes but with obesity or overweight conditions lost, on average, around 15% of their body weight when taking semaglutide at the higher dose (2.4 mg weekly, marketed as Wegovy). For example, a person weighing 220 pounds could expect to lose about 33 pounds.

For people with type 2 diabetes, the weight loss with semaglutide is slightly less but still meaningful. In trials of Ozempic (the diabetes version of semaglutide, usually 0.5 mg to 1 mg weekly), participants lost between 4.5% and 6% of their body weight. That equals about 10 to 14 pounds for someone starting at 220 pounds.

The results suggest that semaglutide is not only effective for lowering blood sugar but also very helpful in weight management. In fact, its weight loss results are considered some of the strongest among medicines in its class.

Clinical Trial Results for Victoza

Victoza (liraglutide) has also been studied for weight effects. At the standard dose for diabetes (1.2 mg to 1.8 mg daily), weight loss tends to be moderate, usually in the range of 5 to 7 pounds over several months. Some people may lose more, while others may lose less, depending on diet, lifestyle, and personal response.

For higher doses, liraglutide is also sold under the brand name Saxenda (3 mg daily). In studies on Saxenda, people lost an average of 5% to 8% of their body weight over one year. This is less than what is seen with semaglutide at the obesity dose but still provides a useful option for many patients.

Direct Comparisons Between the Two

Head-to-head trials help provide the clearest picture. In one large study comparing semaglutide 1 mg weekly with liraglutide 1.8 mg daily, people taking semaglutide lost about twice as much weight as those on liraglutide. Semaglutide patients lost an average of 12 pounds, while liraglutide patients lost about 6 pounds over the same time period.

This finding shows that while both medicines support weight reduction, semaglutide generally leads to more weight loss and is easier to use because it requires fewer injections (once weekly vs. once daily).

Differences in Approval for Obesity Treatment

It is also important to point out that both drugs are approved for weight management but under different brand names and doses:

  • Semaglutide (Wegovy): Approved at a dose of 2.4 mg weekly for people with obesity or overweight with related health problems.

  • Liraglutide (Saxenda): Approved at a dose of 3 mg daily for the same group of patients.

This means that doctors may prescribe either drug depending on availability, insurance coverage, or patient preference. However, the data shows semaglutide at the higher obesity dose tends to produce more weight loss than Saxenda.

What Patients Can Expect

Weight loss is not the same for everyone. Some people respond strongly, while others lose less even with the same medicine. Factors such as diet, exercise, genetics, and other health conditions play a role. Both medicines should always be combined with healthy eating and physical activity for the best results.

Semaglutide users can usually expect greater and more consistent weight loss compared to those on Victoza. However, Victoza and Saxenda still provide a useful option for those who may not tolerate semaglutide, or for those who prefer a daily medication.

Both semaglutide and Victoza help with weight loss, but semaglutide stands out as the stronger option in most studies. This difference explains why Wegovy, the higher-dose form of semaglutide, has become a popular treatment for obesity. Still, Victoza and Saxenda remain important choices, especially when weekly semaglutide is not available or suitable.

Change Your Life Today For Only $249/month

Find out if you qualify
No Hidden Fees, No Contracts
is semaglutide like victoza 4

What Are the Side Effects of Semaglutide and Victoza?

When thinking about starting a new medicine, it is important to understand the possible side effects. Both semaglutide and Victoza belong to the same group of medicines, called GLP-1 receptor agonists. Because they work in similar ways, they also share many side effects. Still, there are some small differences in how people may react to them.

In this section, we will look at the common side effects, the more serious risks, and what patients and healthcare providers should watch for.

Common Side Effects

The most common side effects of both semaglutide and Victoza are related to the stomach and digestive system. Doctors often call these “gastrointestinal side effects.” They include:

  • Nausea: Many people feel sick to their stomach, especially when they first start the medicine or when the dose is increased. Nausea is usually temporary and may get better over time as the body adjusts.

  • Vomiting: Some patients may throw up, often when nausea is strong. This can lead to dehydration if vomiting happens often.

  • Diarrhea: Loose or frequent stools are another common side effect. This can sometimes lead to loss of fluids and electrolytes.

  • Constipation: For others, instead of diarrhea, bowel movements may become hard or infrequent.

  • Abdominal pain or discomfort: Some people report stomach aches, bloating, or gas.

These side effects are usually mild to moderate, and they often improve after a few weeks. Doctors may recommend starting at a low dose and increasing slowly to help the body get used to the medicine. Drinking enough fluids and eating smaller, lighter meals may also help reduce stomach issues.

Differences in Tolerability

While both medicines share similar digestive side effects, studies suggest that semaglutide may cause stronger nausea in some patients compared to Victoza. This may be linked to semaglutide’s longer action in the body, since it stays active for a full week after each injection. However, not everyone experiences this, and many people tolerate semaglutide very well.

Serious Risks

Although rare, there are some serious side effects linked to both semaglutide and Victoza. These include:

  1. Pancreatitis:

    • Both medicines carry a warning about pancreatitis, which is inflammation of the pancreas.

    • Symptoms may include severe stomach pain that does not go away, nausea, vomiting, or pain that moves to the back.

    • Pancreatitis can be life-threatening and requires medical attention right away.

  2. Gallbladder problems:

    • Some people may develop gallstones or gallbladder inflammation (cholecystitis).

    • This can cause upper stomach pain, fever, or yellowing of the skin and eyes (jaundice).

  3. Possible thyroid tumors:

    • Both drugs carry a boxed warning about thyroid C-cell tumors. This warning comes from studies in animals. It is not proven in humans, but doctors avoid prescribing these medicines to people with a personal or family history of medullary thyroid carcinoma or a rare condition called MEN2 (Multiple Endocrine Neoplasia syndrome type 2).

  4. Kidney problems:

    • Severe nausea, vomiting, or diarrhea can sometimes lead to dehydration. This may affect kidney function, especially in people with kidney disease.

Other Possible Side Effects

  • Injection site reactions: Some people may notice redness, swelling, or itching at the place where the medicine was injected.

  • Fatigue: Feeling more tired than usual can occur, though it is less common.

  • Changes in heart rate: A small rise in heart rate has been observed in some patients. The clinical importance of this is still being studied.

What Patients Should Watch For

Patients using semaglutide or Victoza should keep an eye on their symptoms and report concerns to their healthcare provider. Warning signs to seek medical help immediately include:

  • Severe stomach pain that does not improve.

  • Vomiting that will not stop.

  • Signs of dehydration, such as dizziness, fainting, or reduced urination.

  • Swelling in the neck, difficulty swallowing, or a lump in the throat (possible thyroid concern).

  • Sudden chest pain or shortness of breath.

Semaglutide and Victoza share many of the same side effects because they act in a similar way in the body. Most side effects involve the stomach and are temporary, such as nausea, vomiting, or diarrhea. However, rare but serious risks include pancreatitis, gallbladder problems, thyroid tumors, and kidney issues.

While side effects may sound worrying, most people take these medicines safely and with good results. Doctors usually monitor patients closely, especially in the early weeks of treatment. Understanding what to expect helps patients and families stay alert and respond quickly if problems arise.

Who Should Not Use These Medications?

Semaglutide and Victoza are both powerful medicines that help manage type 2 diabetes and, in some cases, obesity. While they are helpful for many people, they are not safe or appropriate for everyone. Knowing who should avoid these drugs is very important because using them in the wrong situations can cause harm. This section explains the main groups of people who should not use semaglutide or Victoza, along with the reasons why.

People with a History of Certain Thyroid Tumors

Both semaglutide and Victoza carry a boxed warning from the U.S. Food and Drug Administration (FDA). This is the strongest type of safety warning. It alerts doctors and patients that these medicines may increase the risk of certain thyroid tumors.

  • Medullary thyroid carcinoma (MTC): People with a personal or family history of this rare type of thyroid cancer should not use semaglutide or Victoza. Studies in animals showed an increased risk of thyroid tumors when these drugs were used, though it is not fully proven in humans.

  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2): This is a genetic condition where people develop tumors in hormone-producing glands, including the thyroid. If someone has MEN2, they should not take these medications.

Because of these risks, doctors often ask about family history of thyroid cancers before prescribing semaglutide or Victoza.

People with a History of Pancreatitis

The pancreas is the organ that makes insulin and digestive enzymes. Semaglutide and Victoza may increase the risk of pancreatitis, which is inflammation of the pancreas.

  • Signs of pancreatitis include severe stomach pain that may spread to the back, nausea, and vomiting.

  • If someone has had pancreatitis before, doctors usually avoid prescribing semaglutide or Victoza. This is because using the drugs could trigger another episode.

People with Severe Gastrointestinal Problems

These medications slow down how fast food leaves the stomach. This is one reason they help reduce appetite and control blood sugar. However, this effect can make some stomach or intestinal problems worse.

  • Gastroparesis: A condition where the stomach muscles do not work well, causing food to stay in the stomach too long. Semaglutide and Victoza can make this condition worse, leading to nausea, vomiting, or bloating.

  • Severe stomach or intestinal disease: People with major digestive problems may not tolerate these medicines well.

Pregnant or Breastfeeding Women

Semaglutide and Victoza are not recommended during pregnancy. Animal studies have shown possible harm to the developing baby. Since human studies are limited, doctors advise against using these medications when pregnant.

  • Women planning to get pregnant are often told to stop semaglutide at least two months before conception. This allows enough time for the drug to leave the body.

  • During breastfeeding, these drugs are also not recommended because it is not known if the medicine passes into breast milk and affects the baby.

Children and Adolescents

Victoza (liraglutide) is approved for children 10 years and older with type 2 diabetes. However, semaglutide is not approved for children with diabetes, though Wegovy (a brand of semaglutide for weight management) is approved for adolescents 12 years and older with obesity.

This means:

  • Semaglutide should not be given to children under 12.

  • For adolescents, it depends on the condition being treated (diabetes vs. obesity).

  • Doctors must carefully weigh risks and benefits before prescribing to younger patients.

Older Adults

There is no strict rule against using semaglutide or Victoza in older adults. However, seniors may be more sensitive to side effects such as nausea, vomiting, or dehydration. For this reason, doctors may start with a lower dose and monitor more closely.

People with Allergies to the Ingredients

Like any medication, semaglutide and Victoza should not be used by people who are allergic to their active ingredients or other ingredients in the injection solution. Allergic reactions may include rash, swelling, or difficulty breathing. In rare cases, severe allergic reactions can occur and require emergency care.

Kidney and Liver Problems

  • Kidney problems: Both semaglutide and Victoza can sometimes cause dehydration due to vomiting or diarrhea. In people with kidney disease, this can make kidney function worse. Doctors may avoid these drugs in patients with advanced kidney disease.

  • Liver problems: These drugs are not directly harmful to the liver, but patients with serious liver conditions may need careful monitoring.

These medications are very effective for many people with type 2 diabetes or obesity, but they are not for everyone. A full medical history and discussion with a healthcare provider are essential before starting semaglutide or Victoza. Doctors weigh the benefits against the risks to make sure the medicine is safe for each individual patient.

How Are They Administered and What Dosing Schedules Should You Know?

Understanding how semaglutide and Victoza are taken is very important. Even though both belong to the same drug family (GLP-1 receptor agonists), the way you take them, how often you take them, and the form they come in are not the same. These differences can affect convenience, comfort, and how well someone follows their treatment plan. In this section, we will go step by step to explain how each medication is used, the devices that deliver them, and what to expect with dosing.

Delivery Methods: Injection and Oral Options

Both semaglutide and Victoza are usually given as injections under the skin (subcutaneous injections). This means the medicine is not swallowed like a pill but instead is placed just beneath the surface of the skin, where it is slowly absorbed into the bloodstream.

  • Semaglutide comes in two main forms:

    • Injectable semaglutide (brand names Ozempic and Wegovy) is given once a week using a pen device.

    • Oral semaglutide (brand name Rybelsus) is the first GLP-1 receptor agonist available as a pill. This gives people who dislike injections another choice.

  • Victoza (liraglutide) is only available as a daily injection. It does not come as a pill. This means people using Victoza must inject themselves every day.

Injection Devices and Technique

Both semaglutide and Victoza use pre-filled, disposable injection pens. These pens are designed to be easy to use, even for people who have never given themselves injections before.

  • Injection sites: The most common places to inject are the stomach area (abdomen), the front of the thighs, or the upper arm. It is important to rotate injection sites each time to avoid irritation under the skin.

  • Needle size: The pens use very small, thin needles, which make the injection less painful. Many people report only a mild sting or no pain at all.

  • Steps to use: The general process includes attaching a new needle, dialing the correct dose, injecting at the chosen site, and then removing and disposing of the needle safely. Health professionals usually provide training to make sure patients are comfortable with the steps.

Frequency of Dosing

How often you need to take the medicine is one of the biggest differences between semaglutide and Victoza.

  • Semaglutide injections (Ozempic and Wegovy): Taken once a week. This weekly schedule is often seen as more convenient. People can choose the same day each week that works best for them, such as every Monday.

  • Oral semaglutide (Rybelsus): Taken once daily, but it must be taken in a very specific way:

    • Take it first thing in the morning, before eating or drinking anything.

    • Swallow it with a small amount of plain water (no more than 4 ounces).

    • Wait at least 30 minutes before eating, drinking, or taking other medications.

  • Victoza: Taken once daily by injection. Some people prefer to take it at the same time each day, such as before breakfast or before bedtime, to make it easier to remember.

Dose Titration (Gradual Increase)

Neither semaglutide nor Victoza starts at the full treatment dose right away. Instead, doctors usually begin with a lower dose and slowly increase it. This is called titration, and it helps the body adjust while lowering the chance of side effects like nausea.

  • Semaglutide (injectable):

    • Start with 0.25 mg once weekly for 4 weeks.

    • Increase to 0.5 mg once weekly.

    • Depending on response and tolerance, the dose may go up to 1 mg or even 2 mg weekly.

  • Oral semaglutide (Rybelsus):

    • Start with 3 mg once daily for 30 days.

    • Increase to 7 mg daily.

    • If more control is needed, the dose may be raised to 14 mg daily.

  • Victoza:

    • Start with 0.6 mg once daily for at least 1 week.

    • Increase to 1.2 mg daily.

    • If needed, the dose may be increased again to 1.8 mg daily.

The slow increase helps reduce side effects but still allows the medicine to reach an effective level for controlling blood sugar and, in some cases, supporting weight loss.

Flexibility and Missed Doses

Real life is busy, and sometimes people miss a dose. Each medication has different rules for what to do if this happens.

  • Semaglutide (injectable): If you miss a dose, you can take it within 5 days of your scheduled time. If more than 5 days have passed, skip it and wait until your next scheduled day.

  • Oral semaglutide (Rybelsus): If you miss a dose, skip it and take the next one the following day. Do not take two doses at once.

  • Victoza: If you miss a dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and continue with your regular schedule.

Convenience and Patient Preference

  • Semaglutide injections may be easier for people who prefer not to think about their medicine every day. Weekly injections can feel less disruptive to daily life.

  • Oral semaglutide appeals to people who dislike needles, but the strict timing rules (empty stomach, waiting period) can be difficult for some.

  • Victoza daily injections provide flexibility, since you can take it at any time of day, with or without food, as long as you are consistent. But the daily injections may feel like a burden for some patients.

Both semaglutide and Victoza require careful dosing and attention to instructions, but the biggest differences are frequency and options. Semaglutide offers both a weekly injection and a pill, while Victoza requires a daily injection. Titration schedules help reduce side effects, and patients should always follow their doctor’s instructions if a dose is missed. Understanding these details helps patients choose the option that best fits their lifestyle and health needs.

Cost and Insurance Coverage: Is One More Affordable?

When people think about starting semaglutide or Victoza, one of the biggest questions is cost. Both of these medicines can be very effective for type 2 diabetes and weight management. But they also come with a high price tag, especially without insurance. Understanding the costs, insurance coverage, and ways to lower the expense can help patients and families make informed choices.

Average Price of Semaglutide

Semaglutide is sold under several brand names, including Ozempic, Wegovy, and Rybelsus. The price depends on the form and dose:

  • Ozempic (weekly injection for type 2 diabetes): The list price in the United States is around $900 to $1,100 per month.

  • Wegovy (weekly injection for obesity treatment): The price is similar, usually $1,300 or more per month.

  • Rybelsus (daily pill for type 2 diabetes): The oral version costs about $900 per month.

These prices are before insurance, discounts, or copay cards. Many patients cannot afford these costs out-of-pocket.

Average Price of Victoza

Victoza is the brand name for liraglutide, a daily injection. Its cost is slightly lower than semaglutide but still high:

  • Victoza (for type 2 diabetes): The monthly cost is usually $800 to $1,000 in the U.S.

  • Saxenda (the weight loss brand of liraglutide): The price is higher, around $1,300 per month, similar to Wegovy.

So, while Victoza may cost a little less than Ozempic, both are considered expensive treatments.

Insurance Coverage for Semaglutide and Victoza

Insurance plays a major role in whether patients can access these drugs. Coverage varies widely:

  • For type 2 diabetes: Most insurance companies, including Medicare and private plans, cover Ozempic and Victoza. They may require a prior authorization, meaning the doctor must prove that the patient has type 2 diabetes and needs this medicine instead of cheaper drugs. Copays can range from $25 to several hundred dollars per month depending on the plan.

  • For obesity treatment: Coverage is more limited. Wegovy and Saxenda are approved by the FDA for weight management, but many insurance plans do not cover weight loss drugs. Patients may have to pay the full price unless their employer or state program includes obesity treatment in benefits. Some commercial plans are starting to expand coverage as the medical benefits of weight loss become clearer.

  • For oral semaglutide (Rybelsus): Coverage is similar to Ozempic because it is also for diabetes. Some plans prefer injectable drugs, while others include pills.

Savings Programs and Manufacturer Discounts

Drug makers often provide savings programs to reduce the cost. For example:

  • Novo Nordisk, the company that makes both semaglutide and liraglutide, offers copay cards that may lower the monthly cost for people with commercial insurance. Some patients pay as little as $25 per prescription.

  • There are patient assistance programs for people with very low income who meet certain qualifications. These programs may provide the drug at no cost.

  • Pharmacies may also offer discount cards that lower prices outside of insurance.

Patients should check eligibility since these programs usually do not apply to Medicare or Medicaid users.

Medicare and Medicaid Considerations

  • Medicare: Typically covers these drugs for type 2 diabetes (Ozempic, Victoza, Rybelsus). However, Medicare does not cover weight loss drugs, which means Wegovy and Saxenda are usually not paid for.

  • Medicaid: Coverage depends on the state. Some states cover GLP-1 drugs for diabetes but not for obesity.

Comparing Affordability Between Semaglutide and Victoza

In most cases:

  • Victoza may cost a little less than Ozempic when comparing list prices, but the difference is not large.

  • Saxenda and Wegovy (the weight loss versions) cost about the same, both being very expensive without coverage.

  • The true cost for patients depends on their insurance and whether savings programs are available.

Generic Availability Outlook

Right now, there are no generic versions of semaglutide or liraglutide. Both remain brand-only medications, which is one reason they are so expensive. Patents for these drugs will not expire for several years. After that, generic competition may reduce prices, but until then, costs are expected to remain high.

Do They Have the Same Cardiovascular Benefits?

One of the most important questions about medicines for type 2 diabetes is whether they protect the heart and blood vessels. This is because people with diabetes have a higher risk of heart disease, stroke, and other cardiovascular problems. Both semaglutide and Victoza (liraglutide) are part of the GLP-1 receptor agonist class, and both have been studied in large clinical trials to see how well they protect the heart. While they share many benefits, there are also some differences in the strength of evidence and the size of the effect.

Why Cardiovascular Outcomes Matter

When new diabetes medicines are developed, they are now required to be tested for safety in people with high risk of heart disease. These studies are called cardiovascular outcomes trials (CVOTs). They look at whether a drug prevents events such as:

  • Heart attack (myocardial infarction)

  • Stroke

  • Hospitalization for heart failure

  • Death from cardiovascular causes

The results of these trials are very important. A medicine that lowers blood sugar but does not protect the heart may not be as useful as one that does both. For semaglutide and Victoza, the trials showed benefits that go beyond blood sugar control.

Victoza (Liraglutide) and the LEADER Trial

For Victoza, the key trial was called LEADER. This study included more than 9,000 people with type 2 diabetes who were at high risk for heart problems. They were followed for about 3.5 to 5 years.

The LEADER trial showed:

  • A 13% reduction in major adverse cardiovascular events (MACE). MACE is a combined outcome of heart attack, stroke, or cardiovascular death.

  • A 22% reduction in cardiovascular death compared to placebo.

  • Lower rates of hospitalization for heart failure, though this effect was smaller.

This trial was a landmark because it was the first time a GLP-1 receptor agonist showed a clear reduction in deaths from cardiovascular causes. For this reason, liraglutide (Victoza) became widely used, especially for patients with diabetes and known heart disease.

Semaglutide and the SUSTAIN-6 Trial

For semaglutide, the first major trial was SUSTAIN-6. This trial included about 3,300 people with type 2 diabetes who were also at high cardiovascular risk. The follow-up period was around two years, shorter than the LEADER trial.

The SUSTAIN-6 trial showed:

  • A 26% reduction in MACE compared to placebo.

  • Strong protection against non-fatal stroke.

  • No significant reduction in cardiovascular death, but the trial was not designed to be long enough to fully measure that outcome.

Because the trial was shorter, researchers could not conclude as firmly about the effect on heart-related death. Still, the results showed clear benefits for preventing strokes and major cardiovascular events.

Longer Studies With Semaglutide

After SUSTAIN-6, more evidence was gathered. For example, in the PIONEER 6 trial of oral semaglutide (Rybelsus), results were consistent with heart safety and possible benefits. More recently, the SOUL and SELECT trials have been designed to provide stronger data on cardiovascular outcomes, especially in people with obesity but without diabetes. The SELECT trial in particular showed that semaglutide reduced the risk of major cardiovascular events in overweight and obese adults who already had heart disease. This broadens the evidence base beyond diabetes.

Comparing the Two Medicines

When looking at cardiovascular benefits, both semaglutide and Victoza stand out compared to many older diabetes drugs. However, there are some differences:

  • Strength of Evidence: Victoza’s LEADER trial proved reductions in cardiovascular death, which makes its benefits very well established. Semaglutide’s SUSTAIN-6 showed strong benefits for stroke prevention and overall cardiovascular events, but it was shorter and not powered to show effects on death. Later trials like SELECT add stronger evidence.

  • Magnitude of Benefit: Both drugs reduce the risk of MACE, but the size of the reduction may differ slightly. Victoza showed about a 13% reduction, while semaglutide showed about 26% in its shorter trial. Because of design differences, it is not fair to directly compare the percentages.

  • Consistency Across Populations: Victoza has more long-term data in people with diabetes and heart disease. Semaglutide now has data in both people with diabetes and people with obesity but no diabetes, making its benefits broader in scope.

Practical Takeaways

For patients with type 2 diabetes who also have heart disease, both semaglutide and Victoza can be very important options. Both lower blood sugar, help with weight loss, and reduce cardiovascular risk. Doctors may choose between them based on other factors, such as dosing schedule (daily vs. weekly), weight management goals, or insurance coverage.

The most important point is that these medicines do more than control blood sugar. They also reduce the risk of serious, life-threatening heart problems. This makes them unique compared to many older diabetes medicines.

Conclusion

When people ask if semaglutide is like Victoza, the answer is both yes and no. They are alike because both medicines belong to the same drug class called GLP-1 receptor agonists. These medicines help the body control blood sugar, support weight loss, and lower the risk of heart problems in some patients. But they are not the same drug. Semaglutide and Victoza have differences in how they are made, how they are taken, how often they are used, and what results people may expect. Understanding these differences can help patients and healthcare providers choose the treatment that is best for each individual.

One of the most important similarities is how both medicines work inside the body. Both semaglutide and Victoza copy the actions of a natural hormone called GLP-1. This hormone is released by the gut after eating. It tells the pancreas to release insulin when blood sugar is high, slows down how quickly food leaves the stomach, and reduces how much glucagon (a hormone that raises blood sugar) is released. Because of this, both medicines lower blood sugar levels and help people feel fuller after meals. These actions explain why they are used for both diabetes control and weight management.

The conditions they are approved to treat overlap, but not completely. Victoza is approved mainly for type 2 diabetes and for lowering cardiovascular risk in patients with type 2 diabetes who already have heart disease. Semaglutide has several forms: Ozempic for type 2 diabetes and heart protection, Wegovy for chronic weight management in people with obesity or overweight plus a health condition, and Rybelsus, which is an oral tablet for type 2 diabetes. This range of options makes semaglutide more flexible for some patients.

Another major difference is how often they are taken. Victoza must be injected every day. Semaglutide injections, on the other hand, are usually taken once a week, which may be easier for many people. There is also an oral semaglutide option, which makes it unique compared to Victoza. Dosing schedules matter a lot because convenience often improves how well patients stay on treatment.

When it comes to blood sugar control, studies show that both drugs are effective, but semaglutide often produces greater reductions in A1C levels compared to liraglutide (Victoza). For weight loss, the differences are even stronger. Semaglutide, especially at higher doses approved for obesity, usually leads to more weight loss than Victoza. This has made semaglutide-based treatments very popular for both diabetes and weight management in recent years.

Side effects are similar, but not identical. Both medicines can cause nausea, vomiting, diarrhea, constipation, and stomach upset. These effects usually happen at the start of treatment and may get better with time. Both medicines also carry warnings about possible risks, such as pancreatitis, gallbladder disease, and thyroid tumors in animal studies. Because they share these risks, doctors carefully review a patient’s health history before prescribing either drug. People with certain conditions, such as a personal or family history of medullary thyroid cancer, should not use either semaglutide or Victoza.

Cardiovascular benefits are another area where both medicines shine. Research shows that liraglutide and semaglutide reduce the risk of serious heart events such as heart attack and stroke in people with type 2 diabetes who are at high cardiovascular risk. This makes them valuable choices not only for managing blood sugar but also for protecting long-term heart health.

Cost and insurance coverage are also important practical points. Both semaglutide and Victoza can be expensive, and coverage may vary by plan. Sometimes insurance companies require prior approval before covering these medications. Because semaglutide comes in multiple branded forms, the exact cost may depend on whether a person is using Ozempic, Wegovy, or Rybelsus. Victoza may be covered differently. Patients often need to check with their insurance provider to understand out-of-pocket costs and access programs.

In the end, both semaglutide and Victoza are effective tools in managing type 2 diabetes and, in some forms, weight. They are similar enough that people may confuse them, but they are not interchangeable in every situation. Semaglutide offers once-weekly injections and an oral option, often stronger effects on weight and blood sugar, and several branded versions for different health needs. Victoza, while older, remains an important daily treatment for type 2 diabetes with strong data supporting its use, especially in people with heart disease.

The choice between these medicines depends on many factors: medical history, treatment goals, convenience, possible side effects, and cost. What works best for one patient may not be right for another. That is why it is important for people to discuss these options with their healthcare provider. A doctor can look at the full picture of someone’s health and decide which medicine may give the best balance of benefits and safety.

In summary, semaglutide and Victoza share a foundation as GLP-1 receptor agonists but differ in dosing, approvals, and strength of effects. Both play a major role in diabetes care today. Knowing the similarities and differences helps patients and families feel more confident and informed when they hear about these treatments. While the details matter, the most important step is making sure treatment is safe, effective, and tailored to the individual’s needs.

Research Citations

Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 327(2), 138–150.

Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., & Vergès, B. (2020). Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & Metabolism, 46(2), 100–109.

Lingvay, I., Desouza, C. V., Lalic, K. S., Rose, L., Hansen, T., Zacho, J., & Pieber, T. R. (2018). A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care, 41(9), 1926–1937.

Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J.; PIONEER 4 Investigators. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): A randomised, double-blind, phase 3a trial. The Lancet, 394(10192), 39–50.

Alsugair, H. A., Alshugair, I. F., Alharbi, T. J., Bin Rsheed, A. M., Tourkmani, A. M., & Al-Madani, W. (2021). Weekly semaglutide vs liraglutide efficacy profile: A network meta-analysis. Healthcare, 9(9), 1125.

Karimi, E., Marmaitar, M., & Salami, N. (2025). Comparative efficacy and safety of semaglutide and liraglutide: A systematic review and meta-analysis of randomized trials. Frontiers in Pharmacology, 16, 1490893.

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). The New England Journal of Medicine, 375(19), 1834–1844.

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., & Bergenstal, R. M.; LEADER Steering Committee; LEADER Trial Investigators. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). The New England Journal of Medicine, 375(4), 311–322.

Lingvay, I., Haiyansyah, S., Lauritsen, T., Hsieh, S., Brown, K., Kumar, A., & Kushner, R. F. (2020). Weight loss with once-weekly semaglutide is independent of baseline demographics and disease characteristics: A mediation analysis vs daily liraglutide. BMJ Open Diabetes Research & Care, 8(2), e001931.

Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021). GLP-1 receptor agonists: An updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism, 12, 2042018821997320.

Change Your Life Today For Only $249/month

Find out if you qualify
No Hidden Fees, No Contracts

Questions and Answers: Is Semaglutide Like Victoza

No, semaglutide and Victoza are not the same drug, but they are similar. Semaglutide is marketed as Ozempic (weekly injection) and Rybelsus (oral tablet), while Victoza is the brand name for liraglutide. Both belong to the GLP-1 receptor agonist class.

Both mimic the hormone GLP-1, which increases insulin release, lowers glucagon, slows digestion, and helps with appetite control. This results in lower blood sugar and potential weight loss.

The main difference is dosing frequency. Semaglutide (Ozempic) is usually injected once weekly, while Victoza (liraglutide) must be injected once daily.

Not exactly. Both are approved for type 2 diabetes, but semaglutide also has FDA approval for weight management at higher doses (Wegovy), while Victoza is mainly indicated for diabetes and reducing cardiovascular risk.

Studies suggest semaglutide generally results in greater weight loss compared to Victoza. That’s why semaglutide has been approved specifically for obesity treatment at higher doses.

They share many side effects, such as nausea, vomiting, diarrhea, and decreased appetite. However, the severity can differ, and semaglutide may be more potent in both effect and side effects.

No, neither is approved for type 1 diabetes or diabetic ketoacidosis. They are only indicated for type 2 diabetes and, in semaglutide’s case, weight management.

Yes, both drugs have cardiovascular benefits. Clinical trials show liraglutide (Victoza) and semaglutide reduce the risk of major adverse cardiovascular events in people with type 2 diabetes and heart disease.

Semaglutide is more convenient for most people because it’s injected once a week, while Victoza requires daily injections.

Yes, under medical supervision. Doctors may recommend switching to semaglutide if better blood sugar control, weight loss, or convenience is desired, but dosing and transition must be carefully managed.

Kevin Kargman

Dr. Kevin Kargman

Dr. Kevin J. Kargman is a pediatrician in Sewell, New Jersey and is affiliated with multiple hospitals in the area, including Cooper University Health Care-Camden and Jefferson Health-Stratford, Cherry Hill and Washington Township. (Learn More)

Skip to content